Patent ID: 8709432
Filing Date: 2014-04-29
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method for increasing the efficacy of cancer therapy comprising administering a therapeutically effective dose of an anti-Folate Receptor 1 (FOLR1) immunoconjugate to a subject having cancer; wherein a tumor sample from the subject exhibits increased expression of FOLR1 using a detection method that distinguishes between staining intensity or staining uniformity in a FOLR1 expressing cancer sample as compared to staining intensity or staining uniformity in one or more reference samples; and wherein the anti-FOLR1 immunoconjugate has the formula (A)-(L)-(C), wherein: (A) comprises an antibody or antigen binding fragment thereof comprising the heavy chain variable domain of SEQ ID NO: 3 and the light chain variable domain of SEQ ID NO: 4 or 5, (L) comprises the linker N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB), and (C) comprises the cytotoxic agent N(2′)-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4), and wherein the linker (L) links (A) to (C).